Hypertention Diagnostics Updating Information to all Shareholders

TORONTO, ON / ACCESSWIRE / June 17, 2020 / Hypertention Diagnostics, Inc.(OTCMKTS:HDII) (“Hypertension Diagnostics” or the “Company”) CEO Liangjian Peng said he received a lot of inquiries about the Company future development. Mr. Peng thanks all inquired people, and he said the company is working on to remove the STOP sign as soon as possible, and switch to Current Pink before implementing any M&A issues.

About Hypertension Diagnostics Inc.

Hypertension Diagnostics, Inc. is a public company currently trading on the OTC Markets (HDII). HDII was originally incorporated in Minnesota.

Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.’ Statements describing objectives or goals or the Company’s future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics Inc.’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostic Inc. periodic reports filed with the regulatory authorities.

CONTACT:

Jeff Peng
Liangjianpeng2018@gmail.com

SOURCE: Hypertension Diagnostics Inc.

View source version on accesswire.com:
https://www.accesswire.com/594203/Hypertention-Diagnostics-Updating-Information-to-all-Shareholders

Staff

Recent Posts

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

50 minutes ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

15 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

18 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

18 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

18 hours ago